AstraZeneca (AZN) Tops Q1 EPS by 139c

AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $2.49, $1.39 better than the analyst estimate of $1.10. Revenue for the quarter came in at $13.59 billion versus the consensus estimate of $13.77 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Centrus Energy signs $900M DOE contract for uranium enrichment
• Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NS